Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/109626GEL, OINTMENT, AND FOAM FORMULATIONS OF TAPINAROF AND METHODS OF USE
WO 27.05.2022
Int.Class A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
Appl.No PCT/US2021/072574 Applicant DERMAVANT SCIENCES GMBH Inventor KALLURI, Haripriya
Embodiments described herein relate to topical pharmaceutical compositions comprising tapinarof, wherein the topical pharmaceutical composition is formulated as an aqueous gel, an anhydrous gel, an ointment, or a foam. Embodiments also relate to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.
2.WO/2022/109047COMPOSITIONS AND METHODS FOR TREATING PULMONARY FIBROSIS
WO 27.05.2022
Int.Class A61K 31/473
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
473ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
Appl.No PCT/US2021/059757 Applicant PULMOSIM THERAPEUTICS LLC Inventor GUPTA, Vivek
The present disclosure relates generally to compositions and methods for preventing, ameliorating or treating pulmonary fibrosis and/or reducing the severity of one or more risk factors, signs, or symptoms associated with pulmonary fibrosis.
3.WO/2022/109062COMPOSITION FOR NAP PROMOTION
WO 27.05.2022
Int.Class A61P 25/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
20Hypnotics; Sedatives
Appl.No PCT/US2021/059778 Applicant NAPJITSU, INC. Inventor FERRARI, John
Provided herein are oral formulations to help create a better power nap. One preferred embodiment of the present invention is a composition that will generally lead to a restorative nap of 30 minutes. Another preferred embodiment is directed to generating a restorative nap in about 10 minutes. One preferred embodiment uses multiple pills with some pills containing a stimulant. By varying the release profile and the substance, it is possible to tailor the nap to the person and to the environment or duration of the nap. We have found that with an embodiment we designate as nootropic Nap 30, seven subjective metrics including tiredness, energy, focus, alertness, feeling good, memory and mood improved over a five-hour period. Compared with coffee or placebo, this Nap 30 composition was more consistent in its effects over time and more stable.
4.WO/2022/106061PHARMACEUTICAL COMBINATIONS COMPRISING A PEPTIDE CXCR4 INHIBITOR AND A TAXANE FOR TREATING CANCER
WO 27.05.2022
Int.Class A61K 38/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides
Appl.No PCT/EP2021/025451 Applicant POLYPHOR AG Inventor ZIMMERMANN, Johann
The present invention relates to pharmaceutical combinations comprising a peptidic CXCR4 inhibitor and a taxane for use in a method for the prevention, delay of progression or treatment of cancer.
5.WO/2022/104621FIXED-DOSE COMBINATION OF SGLT-2 INHIBITOR AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR, AND USE THEREOF
WO 27.05.2022
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No PCT/CN2020/129947 Applicant BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RESEARCH CO. LTD. Inventor JIA, Huijuan
Provided are a fixed-dose combination of an SGLT-2 inhibitor and an angiotensin converting enzyme (ACEI) inhibitor, and the use thereof. The combination comprises: a) an SGLT-2 inhibitor, or a pharmaceutically acceptable salt, a co-crystal, a solvate hydrate or a hydrate thereof; and b) an angiotensin converting enzyme inhibitor, or a pharmaceutically acceptable salt, a co-crystal or a solvate hydrate thereof. The combination is convenient to carry or take, the medication cost is relatively reduced, the risk of overdose or missed medication is avoided, and the medication compliance of patients is improved; the stability is good, especially in terms of it not being easy for polymeric esterified impurities of carboxylic acid in an ACEI (or a degradation product) structure and hydroxy in an SGLT-2 inhibitor structure to form; the probability and safety risk of drug interaction is reduced; and the synergistic effect can be better exerted.
6.WO/2022/105041APPLICATION OF MIR-325 NUCLEIC ACID ANALOG IN PREPARATION OF RELATED PRODUCT FOR TREATING SINUSOIDAL ENDOTHELIAL CELL PATHOLOGICAL DYSFUNCTION
WO 27.05.2022
Int.Class A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Appl.No PCT/CN2021/000004 Applicant XI'AN INSTITUTE OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE Inventor LI, Liya
Provided is an application of an miR-325 nucleic acid analog in the preparation of a related product for treating sinusoidal endothelial cell pathological dysfunction. By directly or indirectly affecting signal pathways by means of miR-325, including recovering the expressions of genes stabilin-2, PTPRM, YWHAQ, etc., of cells, the sinusoidal endothelial cells are re-differentiated to promote the capacity of the sinusoidal endothelial cells for regulating inflammations and resisting activation of stellate cells, thereby effectively relieving vascular diseases.
7.WO/2022/109076DRY POWDER ANTIVIRAL COMPOSITIONS AND THEIR USE FOR TREATING VIRAL INFECTION
WO 27.05.2022
Int.Class A61K 9/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
Appl.No PCT/US2021/059799 Applicant NANO PHARMASOLUTIONS, INC. Inventor OLMSTEAD, Kay
Provided herein are dry powder antiviral compositions, each comprising a microparticle of a pharmaceutically acceptable excipient and nanoparticles of an antiviral, wherein the surface of the microparticle is coated with the nanoparticles. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a viral infection.
8.WO/2022/109106EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS
WO 27.05.2022
Int.Class A61K 31/4433
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4433containing a six-membered ring with oxygen as a ring hetero atom
Appl.No PCT/US2021/059847 Applicant CONSTELLATION PHARMACEUTICALS, INC Inventor BRADLEY, William, D.
Provided herein are methods of treating prostate cancer having at least one pathogenic AR mutation using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6- methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5- carboxamide, or a pharmaceutically acceptable salt thereof, alone or in combination with a therapeutically effective amount of an androgen receptor signaling inhibitor (ARSI) such as enzalutamide.
9.WO/2022/109481METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS
WO 27.05.2022
Int.Class A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
Appl.No PCT/US2021/060584 Applicant ACLARIS THERAPEUTICS, INC. Inventor DECRESCENZO, Gary A.
The present disclosure provides methods of synthesizing a compound of Formula (P)-I. The method proceeds through several different pathways including several novel chiral separations, a Sonogashira coupling, a zinc mediated reductive cyanation, as well as through various halide containing intermediates. Also disclosed is the multi-kilogram preparation of several novel intermediates.
10.WO/2022/109601ACTIVE CANCER IMMUNOTHERAPY BY IMMUNE MODULATION VIA GLOBO SERIES ANTIGENS
WO 27.05.2022
Int.Class G01N 33/574
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
Appl.No PCT/US2021/072513 Applicant OBI PHARMA, INC. Inventor LAI, Ming-Tain
The disclosure provides a method of active immunotherapy for a cancer patient, comprising administering vaccines against Globo series antigens (i.e., Globo H, SSEA-3 and SSEA-4). Specifically, the method comprises administering Globo H-CRM197 (OBI-833/821) in patients with cancer. The disclosure also provides a method of selecting a cancer patient who is suitable as treatment candidate for immunotherapy. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.